In the present study, we found that aberrantly expressed Wnt5a in NLCs leads to resistance to venetoclax in CLL through upregulation of MCL1 and BCL-XL via NF-κB activation. Here, BCL2L1 is linked to B-cell chronic lymphocytic leukemia.